JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Billiontoone (NASDAQ:BLLN) Stock

Billiontoone (NASDAQ:BLLN) had its price target increased by analysts at JPMorgan Chase & Co. from $130.00 to $135.00 in a report released on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 20.12% from the stock’s current price.

A number of other research analysts also recently commented on the stock. Canaccord Genuity Group assumed coverage on shares of Billiontoone in a research report on Wednesday, September 2nd. They set a “buy” rating and a $120.00 target price on the stock. Weiss Ratings cut Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. Zacks Research raised Billiontoone from a “strong sell” rating to a “hold” rating in a report on Friday, October 2nd. BTIG Research restated a “buy” rating and set a $130.00 price target on shares of Billiontoone in a research note on Thursday. Finally, Guggenheim upped their price objective on shares of Billiontoone from $125.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $126.88.

Billiontoone Stock Down 1.3%

Shares of BLLN stock traded down $1.50 during mid-day trading on Thursday, hitting $112.39. The stock had a trading volume of 1,684,843 shares, compared to its average volume of 552,173. Billiontoone has a 12-month low of $61.96 and a 12-month high of $150.44. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. The firm’s 50-day moving average is $104.67 and its two-hundred day moving average is $96.89. The firm has a market capitalization of $5.30 billion and a P/E ratio of 160.56.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting the consensus estimate of $0.15. The firm had revenue of $109.45 million for the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. On average, analysts predict that Billiontoone will post 0.80 earnings per share for the current fiscal year.

Insider Activity at Billiontoone

In related news, CTO David Tsao sold 20,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $109.24, for a total value of $2,184,800.00. Following the transaction, the chief technology officer owned 1,000 shares in the company, valued at approximately $109,240. This represents a 95.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Bosch John Roderick Ten sold 2,834 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $113.17, for a total transaction of $320,723.78. Following the completion of the transaction, the senior vice president owned 16,551 shares in the company, valued at approximately $1,873,076.67. This trade represents a 14.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 264,194 shares of company stock worth $27,797,333 over the last quarter. Insiders own 50.22% of the company’s stock.

Institutional Trading of Billiontoone

A number of hedge funds and other institutional investors have recently made changes to their positions in BLLN. Penn Capital Management Company LLC raised its stake in shares of Billiontoone by 2.3% during the 3rd quarter. Penn Capital Management Company LLC now owns 132,636 shares of the company’s stock valued at $14,143,000 after buying an additional 3,034 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Billiontoone by 86.7% in the 3rd quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $30,000 after buying an additional 130 shares during the period. Provenance Wealth Advisors LLC acquired a new position in shares of Billiontoone in the 3rd quarter valued at about $56,000. D.A. Davidson & CO. purchased a new stake in shares of Billiontoone in the third quarter worth about $773,000. Finally, Forum Financial Management LP purchased a new stake in shares of Billiontoone in the third quarter worth about $274,000.

Key Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q3 results beat estimates: Revenue was about $123 million, ahead of the $115.8 million estimate, and earnings per share also exceeded consensus. BillionToOne Q3 results and guidance
• Positive Sentiment: Higher full-year outlook and upcoming product launch: BillionToOne raised its 2026 revenue guidance to $460 million–$470 million and said it plans to launch Northstar Clear on December 15, supporting expectations for growth. Revenue outlook and Northstar Clear launch
• Neutral Sentiment: BTIG maintained a Buy rating: The firm’s $130 target implies potential upside from the price cited in the report, but it lowered the target from $142, tempering the positive signal. BTIG Research rating
• Negative Sentiment: Executives reported share sales: The CEO, CTO and an SVP sold shares. The transactions were made under pre-arranged Rule 10b5-1 plans, though insider sales can still raise investor concerns about near-term sentiment. Insider transaction report

Billiontoone Company Profile

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.